A nurse is checking the suction control chamber of a client's chest tube and notes that there is no bubbling in the suction control chamber. Which of the following actions should the nurse take?

A. "I'll rinse my mouth after taking this medication."

Montelukast is taken orally and is not associated with the risk of oral thrush or other mouth-related side effects that would require rinsing the mouth after administration. This action is more commonly associated with inhaled corticosteroids, not leukotriene receptor antagonists.

B. "I'll use this medication when I get an asthma attack."

Montelukast is not a rescue medication for asthma attacks. It is a long-term controller medication used to manage and prevent asthma symptoms, not to treat acute attacks. Short-acting bronchodilators such as albuterol are used for quick relief during asthma attacks.

C. "I'll take this medication once a day in the evening."

Montelukast is a leukotriene receptor antagonist commonly used to manage asthma. It is typically taken orally once daily, usually in the evening, to provide 24-hour control of asthma symptoms and improve lung function. Therefore, the statement indicating an understanding of the teaching is option C.

D. "I'll decrease my sodium intake while I'm taking this medication."

Montelukast is not known to affect sodium levels in the body or require any specific dietary modifications, such as decreasing sodium intake. Therefore, this statement is unrelated to the use of montelukast for asthma management

A. Dry mouth

Dry mouth is a common adverse effect of ipratropium (Atrovent) due to its anticholinergic properties. Anticholinergic medications can inhibit saliva production, leading to a sensation of dryness in the mouth. While uncomfortable, dry mouth tends to improve over time as the body adjusts to the medication. Patients can manage dry mouth by increasing fluid intake and practicing good oral hygiene.

B. Anxiety

Anxiety is not a common adverse effect of ipratropium (Atrovent). While some individuals may experience anxiety as a side effect of certain medications, it is not typically associated with ipratropium. If a patient experiences anxiety while taking ipratropium, it is essential to assess whether it may be related to other factors or medications and to consult a healthcare provider for appropriate management.

C. Tachycardia

Tachycardia (rapid heart rate) is not a common adverse effect of ipratropium (Atrovent). While ipratropium is an anticholinergic medication that can affect heart rate in some individuals, tachycardia is not typically reported as a common side effect. However, patients should be monitored for changes in heart rate and other cardiovascular effects while taking ipratropium, especially if they have pre-existing cardiac conditions.

D. Urine retention

Urinary retention is a potential adverse effect of ipratropium (Atrovent) due to its anticholinergic properties. Anticholinergic medications can relax the smooth muscle of the bladder, leading to difficulty emptying the bladder completely. However, urinary retention is less common with ipratropium compared to other anticholinergic medications, such as those used to treat overactive bladder. Patients experiencing urinary retention while taking ipratropium should consult their healthcare provider for further evaluation and management.